[Development of anti-tumor blood vessel antibodies by phage display method]

Takuya Yamashita1, Naoki Utoguchi, Ryo Suzuki

  • 1Department of Biopharmaceutics, Teikyo University, Kanagawa, Japan. t-yamashita@nibio.go.jp

Insights

Researchers developed novel tumor endothelial cell (TEC) antibodies using phage display technology. These targeted antibodies show potential for delivering anti-cancer drugs, offering a new approach in cancer therapy.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Context:

  • Tumor blood vessels are critical for cancer progression and represent a key therapeutic target.
  • Developing targeted therapies that specifically attack tumor vasculature is a significant challenge in oncology.

Purpose:

  • To generate specific monoclonal antibodies targeting tumor endothelial cells (TECs).
  • To create a phage antibody display library for isolating TEC-specific single-chain variable fragments (scFvs).

Summary:

  • A phage antibody display library of approximately 1.3x10^7 CFU was constructed from TEC-immunized mice.
  • Cell panning and subtractive panning enriched for TEC-specific scFv phage clones, increasing binding affinity by 10,000-fold.
  • One selected scFv clone demonstrated high specificity for TECs in vitro and accumulated preferentially in tumor tissues in vivo.

Impact:

  • The isolated TEC-specific antibody and its target molecule show promise for developing novel anti-cancer therapies.
  • This approach could lead to more effective drug delivery systems targeting tumor vasculature.